J Psychiatry Neurosci January-February 2021;46(2):E208-E209 | PDF
Amy Pipe, MB; Beth Patterson, MSc; Michael Van Ameringen, MD
Affiliations: From the School of Medicine, University College Cork, Cork, Ireland (Pipe); the MacAnxiety Research Centre, McMaster University, Hamilton, Ont., Canada (Patterson); and the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ont., Canada (Van Ameringen).
Competing interests: M. Van Ameringen has received personal fees for serving on the advisory boards of Allergan, Almatica, Brainsway, Lundbeck, Myriad Neuroscience, Otsuka and Purdue Pharma (Canada); speaker fees from Allergan, Lundbeck, Purdue Pharma (Canada) and Pfizer; a Hamilton Academic Health Sciences Organization Innovation Grant; a research grant from Purdue Pharma (Canada); and clinical trial funding from Janssen-Ortho Inc. A. Pipe and B. Patterson declare no competing interests.
Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e. research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/